#	Pagina
attuale pagina	/open-h2020/projects/217440/index.html

Opendata, web and dolomites

CG01 SIGNED

A novel gene therapy for epilepsy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CG01 project word cloud

Explore the words cloud of the CG01 project. It provides you a very rough idea of what is the project "CG01" about.

translate cells vision virus 30 epileptics care valid medicinal adeno receptor safe europeans genes patients neuropeptide trial cg mediated afflicted npy standard brain innovation epilepsy combigene encode eur germany alone fulfilling uk introduction clinical integral aav approximately 15 validate animal million date epileptic upregulation y2 data people human cure symptoms unresponsive france resistant anti strategic gene cg01 therapy clinically company basis worldwide aed vector commercialisation annually validated shown revolutionize aligned treatment billion inspired drug entails alleviate seizures operations inhibits delivering

Project "CG01" data sheet

The following table provides information about the project.

Coordinator	COMBIGENE AB Organization address address: MEDICON VILLAGE city: LUND postcode: 223 81 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	https://combigene.com/en/
Total cost	4˙801˙925 €
EC max contribution	3˙361˙347 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-08-01 to 2021-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	COMBIGENE AB COMBIGENE AB Organization address address: MEDICON VILLAGE city: LUND postcode: 223 81 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	coordinator	3˙361˙347.00

Map

Project objective

The aim of this project is to clinically validate CG01 as a novel gene therapy for the treatment of drug-resistant epilepsy patients. Epilepsy affects approximately 50 million people worldwide. 6 million Europeans are afflicted by the condition which annually costs around EUR 15 billion in France, Germany and the UK alone. Current standard of care entails anti-epileptic drug (AED) therapy. However, up to 30% of epileptics (20 million people worldwide) are unresponsive. Research to date has shown that adeno-associated virus (AAV) vector-mediated upregulation of the human neuropeptide Y (NPY) and its receptor Y2 inhibits epileptic seizures. This has inspired CG to develop CG01, a type of advanced therapy medicinal product based on the introduction of genes that encode human NPY and Y2 via the AAV vector into the brain cells of epileptic patients. AAV has already been shown as clinically safe and validated gene delivery system. The current project aims to translate promising findings in animal research into valid human data by bringing CG01 through a Phase I/II trial in drug resistant epilepsy patients. This will be the basis for further clinical development and commercialisation of the product. CombiGene’s strategic operations are currently aligned to establish CG01 as a novel epilepsy treatment. This innovation has the potential to revolutionize treatment for epileptics by delivering a treatment that may cure rather than just alleviate symptoms. Developing CG01 is integral to the company’s growth and this project is therefore essential in fulfilling the company’s long term vision.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CG01" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CG01" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.